Trinity Partners worked with Sage Therapeutics to explore the burden of illness for super-refractory status epilepticus patients.

Executives from Trinity Partners and Sage Therapeutics conducted a study to provide an estimate of the annual number of super-refractory status epilepticus (SRSE) cases in the US and to evaluate utilization of hospital resources by these patients, using hospital chargemaser data. The study suggests that SRSE is associated with high mortality and morbidity, and significant use of healthcare resources. Read the full report here:

See all Thought Leadership posts